Division of Cardiovascular Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
Am J Hypertens. 2010 Mar;23(3):260-8. doi: 10.1038/ajh.2009.255. Epub 2009 Dec 31.
Central blood pressure (CBP) has been reported to be superior to brachial blood pressure (BP) as a cardiovascular risk predictor in hypertensive patients; however, the effects of antihypertensives on CBP have not been fully examined. This cross-sectional hypothesis-generating study aimed to tentatively characterize all classes of antihypertensives in relation to CBP.
Calibrated tonometric radial artery pressure waveforms were recorded using an automated device in 1,727 treated hypertensive patients and 848 nonhypertensive (non-HT) participants. Radial artery late systolic BP (SBP) has been reported to reflect central SBP. The difference between late and peak SBPs (DeltaSBP2) was assessed with linear regression model-based adjustments. Separate regression models for DeltaSBP2 were constructed for both participant groups as well as specified sub-populations.
DeltaSBP2 was 3.3 mm Hg lower in patients treated with any single-vasodilating (VD) antihypertensive agent without significant interclass difference than with non-VD agents, and was 2.0 mm Hg lower than estimated in nonhypertensive subjects. Combinations of two vasodilators were 6.6 and 2.9 mm Hg lower in DeltaSBP2 than nonvasodilator combinations and nonhypertensive subjects, respectively (P < 0.001 for all comparisons). Nonvasodilators and their combination showed high DeltaSBP2, 1.1 and 3.7 mm Hg higher than in nonhypertensive subjects (P < 0.001 for both). Additional adjustment of the pulse rate reduced high DeltaSBP2 with beta-blockers (betaBLs).
This cross-sectional observation suggests that vasodilatory antihypertensives lower CBP independently of peripheral BP levels without evident class-specific differences, whereas nonvasodilators may raise CBP.
中心血压(CBP)已被报道在高血压患者中作为心血管风险预测因子优于肱动脉血压(BP);然而,降压药对 CBP 的影响尚未得到充分研究。这项横断面假设产生研究旨在初步描述与 CBP 相关的所有降压药类别。
在 1727 名接受治疗的高血压患者和 848 名非高血压(非 HT)参与者中,使用自动设备记录校准的示波桡动脉压力波形。已经报道了桡动脉晚期收缩压(SBP)反映中心 SBP。使用基于线性回归模型调整的方法评估晚期和峰值 SBP 之间的差异(DeltaSBP2)。为参与者组和指定的亚人群分别构建了用于 DeltaSBP2 的单独回归模型。
与使用非血管扩张剂(VD)降压药的患者相比,任何单一血管扩张剂(VD)降压药治疗的患者的 DeltaSBP2 低 3.3mmHg,且与非高血压患者相比低 2.0mmHg。两种血管扩张剂的组合在 DeltaSBP2 中比非血管扩张剂组合和非高血压患者低 6.6 和 2.9mmHg(所有比较均 P<0.001)。非血管扩张剂及其组合的 DeltaSBP2 较高,比非高血压患者高 1.1 和 3.7mmHg(均 P<0.001)。对脉搏率的额外调整降低了β受体阻滞剂(βBLs)的高 DeltaSBP2。
这项横断面观察表明,血管扩张性降压药独立于外周血压水平降低 CBP,而无明显的类别特异性差异,而非血管扩张剂可能升高 CBP。